阿托伐他汀对血管软斑的临床疗效观察

Clinical Effect of Atorvastatin on Vascular Soft Spot

目的探讨阿托伐他汀对血管软斑的临床疗效分析。方法纳入2017年1月-2021年1月于我院治疗的高血压合并颈动脉斑块的患者68例作为研究对象,通过随机数字表法均分为两组,各34例。对照组仅给予生活干预,研究组在此基础上服用阿托伐他汀进行治疗,对比两组患者治疗前后血管超声技术检查结果、血脂水平、不良反应发生率变化情况。结果两组患者患者前IMT、斑块面积、血脂相关指标等均无显著差异(P>0.05);治疗后,两组患者IMT、斑块面积均有所下降(t=13.865,8.250,3.285,2.399,P<0.05),研究组较对照组更低(t=5.568,5.507,P<0.05);治疗前,两组血脂指标无显著差异(P>0.05);治疗后,两组患者血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)及低密度脂蛋白胆固醇(LDL-C)水平均较治疗前明显改善(t=15.791,20.198,11.794,16.034,P<0.05),研究组较对照组改善更显著(t=5.708,10.522,P<0.05)研究组患者2例患者出现便秘、胃肠胀气,未予治疗逐渐恢复;对照组中3例患者出现便秘、6例患者出现头晕、4例出现腹痛,经对症治疗后均好转。研究组不良反应发生率为5.88%显著低于对照组35.29%(χ^(2)=8.995,P<0.05)。结论阿托伐他汀治疗血管软斑的临床疗效确切,可显著降低患者的血脂水平,改善影像学检查结果,且不良反应较少,安全性较高,值得推广。

Objective To investigate the clinical effect of atorvastatin on soft spots in blood vessels.Methods A total of 68 patients with hypertension combined with carotid plaque who were treated in our hospital from January 2017 to January 2021 were included as the research subjects.They were divided into two groups,34 in each group,by random number table.The control group was only given life intervention,while the research group was additionally given atorvastatin.The results of vascular ultrasound examination,blood lipid levels and the incidence of adverse reactions in the two groups before and after treatment were compared.Results There was no significant difference in IMT,plaque area and lipid-related indexes between the two groups(P>0.05).After treatment,the IMT and plaque area of the two groups were decreased(t=13.865,8.250,3.285,2.399,P<0.05),which were lower in the research group than in the control group(t=5.568,5.507,P<0.05).Before treatment,there was no significant difference between the two groups in blood lipid indexes(P>0.05).After treatment,serum Total cholesterol(TC),Triacylglycerol(TG),high density lipoprotein cholesterol(HDL-C)and low density lipoprotein cholesterol(LDL-C)levels were significantly improved compared with those before treatment(t=15.791,20.198,11.794,16.034,P<0.05).The improvement in the research group was more significant than that in the control group(t=5.708,10.522,P<0.05).Two patients in the research group experienced constipation and flatulence,and they gradually recovered without treatment.In the control group,three patients experienced constipation,six patients experienced dizziness and four patients experienced abdominal pain,all of which were improved after symptomatic treatment.The incidence of adverse reactions in the treatment group was 5.88%,which was significantly lower than 35.29%in the control group(χ^(2)=8.995,P<0.05).Conclusion The clinical effect of atorvastatin in the treatment of vascular soft spot is reliable,it can significantly reduce blood lipid levels of patients and improve imaging results,and with less adverse reactions,high safety,it is worthy of promotion.